Merck & Co., Inc. (MRK)
Merck: 'Strong Buy' Lipfendra FDA First And Continued Oncology Expansions
Merck & Co., Inc. maintains a Strong Buy rating, driven by robust oncology expansion and the launch of LIPFENDRA, the first oral PCSK9 inhibitor for hypercholesterolemia. Company's oncology pipeline advances with FDA acceptance of four regulatory filings, including ifinatamab deruxtecan, and strategic acquisitions like Terns to counter KEYTRUDA's 2028 patent expiry. LIPFENDRA targets statin-treated patients needing further LDL-C reduction, with peak sales potential estimated at $5 billion by 2034, strengthening MRK's cardiometabolic portfolio.
MRK Stock Jumps on FDA Nod for Cholesterol-Lowering Pill
Merck shares climb after the FDA approved Lipfendra, the first oral PCSK9 inhibitor for lowering LDL cholesterol, with the launch expected in weeks.
The First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?
The FDA's approval of Merck (NYSE:MRK | MRK Price Prediction) enlicitide decanoate, marketed as Lipfendra, marks the first once-daily oral PCSK9 inhibitor cleared for adults with high LDL cholesterol, including heterozygous familial hypercholesterolemia.
New Cholesterol Pill, Earnings Growth Boost Merck Shares
Shares of Merck & Co., Inc. (MRK) rise 3,453% since 1990 thanks to institutional investors.
FDA signs off on Merck's cholesterol-lowering pill — the first oral treatment of its kind
The pill, branded as Lipfendra, is intended to treat patients with hypercholesterolemia, including those with hereditary forms of the disease, which causes elevated levels of LDL.
FDA Expands MRK & PFE's Keytruda-Padcev Combo Use in Bladder Cancer
Merck's Keytruda in combination with Pfizer's Padcev wins FDA nod for expanded use in muscle-invasive bladder cancer, regardless of cisplatin eligibility.
Merck (MRK) Stock Sinks As Market Gains: Here's Why
In the closing of the recent trading day, Merck (MRK) stood at $123.54, denoting a -1.22% move from the preceding trading day.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
MRK Surpasses 50- & 200-Day SMAs: Buy, Hold or Sell at Current Levels?
MRK trades above its 50- and 200-day SMAs as pipeline progress, acquisitions and Keytruda strength offset patent and vaccine headwinds.
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade
Merck (MRK) concluded the recent trading session at $126.78, signifying a -2.15% move from its prior day's close.
Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
